| INTRODUCTION
Unlike acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs) have generally been thought to be associated with increased risk of IBD exacerbation. Use of NSAIDs is known to be associated with mucosal ulcers in the gastrointestinal tract. [1] [2] [3] In addition, chronic use of NSAIDs has previously been linked to development of Crohn's disease (CD) and ulcerative colitis (UC). [4] [5] [6] [7] In clinical practice, patients with established IBD are encouraged to avoid the use of NSAIDs because of the concern for their potential adverse effects on disease activity and instead are encouraged to use acetaminophen for management of pain. Although several studies have examined the link between NSAIDs use and IBD exacerbation, the results have been conflicting. 6, 8, 9 We therefore sought to conduct a systematic review and meta-analysis of prior studies | 1429 2 | ME TH ODS
| Search strategy
We conducted a systematic literature search using a predetermined and registered protocol (Data S1) in accordance with the Preferred
Reporting Items for Systematic review and Meta-Analysis (PRISMA) statement. 10, 11 For electronic database search, we used medical subject headings (MeSH) and text words related to acetaminophen, NSAIDs, cyclooxygenase (COX-2) inhibitors, CD, and UC for MEDLINE (PubMed interface, 1974-March 2017) (Data S1) and Embase subject headings (Emtree) for EMBASE. 
| Data extraction
Our primary outcome was defined as IBD disease activity or complications while our primary exposure was use of acetaminophen, NSAIDs, or COX-2 inhibitors. There were significant variations in the outcome variable measures among studies, which included rates of hospitalisations and exacerbation, and changes in disease-specific activity index scores. Other variables extracted included study design, duration and frequency of exposure, publication year, and information on key indicators of study quality using NewcastleOttawa scale (NOS). We extracted reported odds ratios (ORs), hazard ratios (HRs), rate ratios (RRs) and incidence rate ratios (IRRs) with their respective 95% CIs or data enabling the calculation of these association measures. Both adjusted and unadjusted values were extracted; though, when available, the adjusted estimates were used.
| Statistical analysis
Meta-analysis summary estimates (RR) and 95% CIs were obtained by pooling effect estimates (RRs, IRRs, HRs and ORs) from all the eligible studies using fixed-or random-effects meta-analysis according to the method of Desimonian and Laird. 13 Given the relatively modest prevalence of IBD and its complications, the OR is a good approximate of the RR under the rare outcome assumption. 14 To assess for heterogeneity of RRs across studies, I 2 statistics were calculated. 15 Given the small number of studies included in the metaanalysis, random effect models were used when there was moderate heterogeneity between studies, defined as I 2 value ≥ 30%. 15 We assessed for publication bias using Egger's test, and funnel plot for 33 and two cohort 9, 27 and three case-control studies. 8, 21, 26 Due to the inherent qualitative differences among studies, we conducted quality assessment using NewcastleOttawa scale (Tables S1 and S2 ). Studies with a score ≥7 were considered to have low risk of bias, consistent with prior definitions. 
| Systematic review of COX-2 inhibitors use and IBD exacerbation
Our study captured eight articles evaluating selective COX-2 inhibitor use and IBD exacerbation (Table 3) . We did not conduct a metaanalysis because of insufficient data. Specifically, three of the studies had no comparator group, 35, 36, 38 one study utilised patients with dyspepsia as controls 37 while another study used acetaminophen exposure as control. 33 Studies by Mahadevan et al, 35 Reinisch et al 38 and Takeuchi Felder (2000) Bonner (2000) Hensley (2015) Long (2016) Subtotal (I-squared = 60.3%, P = 0.039) Ulcerative colitis .
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| Sensitivity analyses
We considered the possibility that quality of studies may have been a major source of substantial heterogeneity observed across the studies and therefore performed sensitivity analysis limiting our studies to those with a score of ≥7 on the Newcastle-Ottawa scale (Figure 4 ). The Hensley (2015) Subtotal (I-squared = 0.0%, P = 0.825) 
| Publication bias
We assessed for presence of publication bias using Egger's test and found no evidence for publication bias (P values of Egger's test = 0.952 for CD, 0.699 for UC and 0.239 for IBD).
| DISCUSSION
In this systematic review and meta-analysis of prior studies, we found no consistent association between acetaminophen, NSAIDs or COX-2 inhibitor use and risk of CD and UC exacerbation. However, among studies with low risk of bias, NSAIDs use appeared to be associated with increased risk of exacerbation in CD, but not UC.
Although we observed significant heterogeneity between the studies, likely due to variation in outcome ascertainment, we found no evidence for publication bias.
American College of Gastroenterology guidelines for management of IBD recognise NSAIDs as potential triggers for disease exacerbation, highlighting the ongoing concern regarding the use of these medications in patients with established disease. 41 Although, it's well-established that NSAIDs may cause de novo damage throughout the gastrointestinal tract, [42] [43] [44] [45] the precise mechanism through which NSAIDs promote IBD exacerbation remains largely unknown. Prior studies have suggested that inhibition of intestinal prostaglandin synthesis due to dual inactivation of COX-1 and COX-2 enzyme isoforms may in part be responsible. 33, 46 It is however unclear whether COX-1 inhibition is primarily responsible for mucosal injury and whether patients taking COX-2 inhibitors have similar potentially increased risk of exacerbation compared to those consuming nonselective NSAIDs. 47 In our systematic review, we did not Source Crohn's disease Evans (1997) Hensley (2015) Long (2016) .
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. Evans et al, 6 Hensley et al 8 and Long et al, 9 which appeared to have the most rigorous study designs suggested a positive association.
However, even in well-designed, studies, there were significant limitations in definition of outcomes. For example, in the study by Evans et al, 6 exacerbation was defined as emergency admission to hospital.
This definition is unlikely to capture the majority of CD exacerbations that are managed in the out-patient settings. 48 In contrast, Hensley Our study has several strengths that are worth noting. First, this study followed the recommendations for rigorous systematic review and had a pre-defined and published protocol. 10, 11, 15 9 and there is a 40% rate of IBD exacerbation among non-NSAIDs users, 52, 53 we estimated that our metaanalysis had over 80% power to detect a minimum RR of 1.1 at a significance level of 0.05. We recognise that IBD is a heterogeneous disease and therefore, there may be subgroups of patients particularly at risk of disease exacerbations with use of NSAIDs.
Therefore, future studies focused on examining predictors of disease exacerbations/progression with use of NSAIDs are needed.
Lastly, our work was based on studies reported in English language and though we did not find any non-English reported studies, we acknowledge this may limit generalisability of our findings to populations in geographic regions not well represented by English language literature.
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